- Home
- SEER vs MCRB Comparison
SEER vs MCRB Comparison
Compare SEER & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- MCRB
- Stock Information
- Founded
- SEER 2017
- MCRB 2010
- Country
- SEER United States
- MCRB United States
- Employees
- SEER N/A
- MCRB N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- MCRB Health Care
- Exchange
- SEER Nasdaq
- MCRB Nasdaq
- Market Cap
- SEER 135.0M
- MCRB 131.0M
- IPO Year
- SEER 2020
- MCRB 2015
- Fundamental
- Price
- SEER $2.27
- MCRB $0.82
- Analyst Decision
- SEER Hold
- MCRB Buy
- Analyst Count
- SEER 1
- MCRB 4
- Target Price
- SEER $3.00
- MCRB $5.63
- AVG Volume (30 Days)
- SEER 150.7K
- MCRB 2.2M
- Earning Date
- SEER 02-27-2025
- MCRB 03-04-2025
- Dividend Yield
- SEER N/A
- MCRB N/A
- EPS Growth
- SEER N/A
- MCRB N/A
- EPS
- SEER N/A
- MCRB N/A
- Revenue
- SEER $14,608,000.00
- MCRB $126,325,000.00
- Revenue This Year
- SEER N/A
- MCRB N/A
- Revenue Next Year
- SEER $34.78
- MCRB N/A
- P/E Ratio
- SEER N/A
- MCRB N/A
- Revenue Growth
- SEER N/A
- MCRB 12856.41
- 52 Week Low
- SEER $1.51
- MCRB $0.54
- 52 Week High
- SEER $2.63
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- SEER 41.78
- MCRB 49.17
- Support Level
- SEER $2.29
- MCRB $0.79
- Resistance Level
- SEER $2.39
- MCRB $0.91
- Average True Range (ATR)
- SEER 0.08
- MCRB 0.08
- MACD
- SEER -0.01
- MCRB 0.00
- Stochastic Oscillator
- SEER 14.42
- MCRB 49.67
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.